Blurbs

Analysts’ Top Healthcare Picks: Lineage Cell Therapeutics (LCTX), Compugen (CGEN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Cell Therapeutics (LCTXResearch Report), Compugen (CGENResearch Report) and Eli Lilly & Co (LLYResearch Report) with bullish sentiments.

Lineage Cell Therapeutics (LCTX)

Robert W. Baird analyst Jack Allen initiated coverage with a Buy rating on Lineage Cell Therapeutics on November 14 and set a price target of $5.00. The company’s shares closed last Tuesday at $1.31.

According to TipRanks.com, Allen has 0 stars on 0-5 stars ranking scale with an average return of -23.1% and a 24.1% success rate. Allen covers the Healthcare sector, focusing on stocks such as Frequency Therapeutics, Intellia Therapeutics, and Allogene Therapeutics.

Lineage Cell Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $5.40, representing a 285.7% upside. In a report issued on November 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.

See today’s best-performing stocks on TipRanks >>

Compugen (CGEN)

SVB Securities analyst Daina Graybosch maintained a Buy rating on Compugen on November 14 and set a price target of $8.00. The company’s shares closed last Tuesday at $0.87, close to its 52-week low of $0.51.

According to TipRanks.com, Graybosch is ranked 0 out of 5 stars with an average return of -17.4% and a 32.4% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Molecular Partners, and LAVA Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Compugen with a $6.67 average price target, representing a 694.0% upside. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $8.00 price target.

Eli Lilly & Co (LLY)

SVB Securities analyst David Risinger maintained a Buy rating on Eli Lilly & Co on November 14. The company’s shares closed last Tuesday at $349.95, close to its 52-week high of $369.80.

According to TipRanks.com, Risinger is a 4-star analyst with an average return of 13.7% and a 74.5% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Horizon Therapeutics, and Theravance Biopharma.

Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $379.85, representing a 6.4% upside. In a report issued on November 14, Truist Financial also maintained a Buy rating on the stock with a $421.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LCTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More